Klin Monbl Augenheilkd 2019; 236(10): 1192-1200
DOI: 10.1055/a-0577-7925
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Die Lasertrabekuloplastik in der modernen Glaukomtherapie – ein Überblick

Laser Trabeculoplasty in Modern Glaucoma Therapy – a Review
Roman Greslechner
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg
,
Detlev Spiegel
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg
› Author Affiliations
Further Information

Publication History

eingereicht 20 November 2017

akzeptiert 06 February 2018

Publication Date:
11 April 2018 (online)

Zusammenfassung

Hintergrund Die Lasertrabekuloplastik (LTP) stellt neben medikamentöser Therapie und operativen Interventionen eine etablierte Behandlungsmodalität in der Therapie chronischer Offenwinkelglaukome dar. Dabei besteht eine große Variabilität in der praktischen Anwendung.

Methoden Literaturrecherche über PubMed. Darstellung der wichtigsten evidenzbasierten Daten zur Lasertrabekuloplastik.

Ergebnisse Argonlasertrabekuloplastik (ALT) und selektive Lasertrabekuloplastik (SLT) stellen sichere und effektive Verfahren dar, die zu einer Drucksenkung um 20 – 30% führen. Vergleichbare Erfolgsraten werden für beide Prozeduren berichtet. Im Verlauf muss bei 50% mit einem Therapieversagen nach ca. 2 – 5 Jahren gerechnet werden. Die Wiederholung einer ALT ist mit einer deutlich geringeren Drucksenkung und Wirkdauer verbunden. Auch die Wiederholung einer SLT ist mit einem Wirkverlust verbunden. Die Wirksamkeit der SLT nach initialer ALT konnte nachgewiesen werden, wohingegen Daten zur Wirksamkeit einer ALT nach initialer SLT noch fehlen. Bei fortgeschrittenen Glaukomen unter maximaler medikamentöser Therapie wurden in Hinblick auf zusätzliche Interventionen schlechtere Erfolgsraten berichtet.

Schlussfolgerung Die LTP bietet sich als Ersttherapie und ergänzende Therapie in allen Stadien an. Bei fortgeschrittenen Glaukomen unter maximaler medikamentöser Therapie sind die Erfolgsaussichten aufgrund der notwendigen niedrigen Zieldrücke eingeschränkt.

Abstract

Background Laser trabeculoplasty (LTP) is a well established treatment modality in the management of chronic open angle glaucoma. Nonetheless there is much variation in practice.

Methods A literature search in the PubMed database was conducted and the most important evidence-based results were summarised.

Results Argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) are safe and effective treatment modalities, achieving an IOP reduction of 20 – 30%. Similar success rates have been reported for both procedures. A 50% rate of failure occurs after 2 – 5 years. Repeat-ALT is associated with a lower IOP decrease and a shorter duration of treatment effect. Repetition of SLT after initial SLT seems to be associated with loss of efficiency as well. SLT has been shown to be successful after initial ALT, whereas there are no data on ALT after initial SLT. For advanced glaucoma on maximum medical therapy, low success rates have been reported with regard to additional interventions.

Conclusion LTP is a good option for initial and adjunctive treatment. In advanced glaucoma on maximum medical therapy, low target pressures are needed, and filtering surgery has to be considered.

 
  • Literatur

  • 1 Zweng HC, Flocks M. Experimental photocoagulation of the anterior chamber angle. A preliminary report. Am J Ophthalmol 1961; 52: 163-165
  • 2 Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol 1972; 3: 27-31
  • 3 Worthen DM, Wickham MG. Laser trabeculotomy in monkeys. Invest Ophthalmol 1973; 12: 707-711
  • 4 Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol 1979; 97: 319-322
  • 5 The Glaucoma Trail Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology 1990; 97: 1403-1413
  • 6 Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res 1995; 60: 359-371
  • 7 Latina MA, Sibayan SA, Shin DH. et al. Q-switched 532-nm Nd : YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 1998; 105: 2082-2088
  • 8 Cvenkel B, Hvala A, Drnovsek-Olup B. et al. Acute ultrastructural changes of the trabecular meshwork after selective laser trabeculoplasty and low power argon laser trabeculoplasty. Lasers Surg Med 2003; 33: 204-208
  • 9 Wood JPM, Plunkett M, Previn V. et al. Rapid and delayed death of cultured trabecular meshwork cells after selective laser trabeculoplasty. Lasers Surg Med 2010; 42: 326-337
  • 10 Melamed S, Pei J, Epstein DL. Short-term effect of argon laser trabeculoplasty in monkeys. Arch Ophthalmol 1985; 103: 1546-1552
  • 11 Melamed S, Pei J, Epstein DL. Delayed response to argon laser trabeculoplasty in monkeys. Morphological and morphometric analysis. Arch Ophthalmol 1986; 104: 1078-1083
  • 12 van der Zypen E, Fankhauser F. Ultrastructural changes of the trabecular meshwork of the monkey (Macaca speciosa) following irradiation with argon laser light. Graefes Arch Clin Exp Ophthalmol 1984; 221: 249-261
  • 13 Mchugh D, Marshall J, Ffytche TJ. et al. Ultrastructural changes of human trabecular meshwork after photocoagulation with a diode laser. Invest Ophthalmol Vis Sci 1992; 33: 2664-2671
  • 14 Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001; 108: 773-779
  • 15 Wang W, He M, Zhou M. et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One 2013; 8: e84270
  • 16 Van Buskirk EM, Pond V, Rosenquist RC. et al. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology 1984; 91: 1005-1010
  • 17 Bradley JM, Anderssohn AM, Colvis CM. et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci 2000; 41: 422-430
  • 18 Latina MA, de Leon JMS. Selective laser trabeculoplasty. Ophthalmol Clin North Am 2005; 18: 409-419 vi
  • 19 Bylsma SS, Samples JR, Acott TS. et al. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol 1988; 106: 544-547
  • 20 Acott TS, Samples JR, Bradley JM. et al. Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty. Am J Ophthalmol 1989; 107: 1-6
  • 21 Bylsma SS, Samples JR, Acott TS. et al. DNA replication in the cat trabecular meshwork after laser trabeculoplasty in vivo. J Glaucoma 1994; 3: 36-43
  • 22 Dueker DK, Norberg M, Johnson DH. et al. Stimulation of cell division by argon and Nd : YAG laser trabeculoplasty in cynomolgus monkeys. Invest Ophthalmol Vis Sci 1990; 31: 115-124
  • 23 European Glaucoma Society. ed. Terminology and Guidelines for Glaucoma. 4th ed. SvetPrint d.o.o., printed in EU 2014. European Glaucoma Society; 2014
  • 24 Habib L, Lin J, Berezina T. et al. Selective laser trabeculoplasty: does energy dosage predict response?. Oman J Ophthalmol 2013; 6: 92-95
  • 25 Wilensky JT, Weinreb RN. Low-dose trabeculoplasty. Am J Ophthalmol 1983; 95: 423-426
  • 26 Schwartz LW, Spaeth GL, Traverso C. et al. Variation of techniques on the results of argon laser trabeculoplasty. Ophthalmology 1983; 90: 781-784
  • 27 Weinreb RN, Ruderman J, Juster R. et al. Influence of the number of laser burns administered on the early results of argon laser trabeculoplasty. Am J Ophthalmol 1983; 95: 287-292
  • 28 Lustgarten J, Podos SM, Ritch R. et al. Laser trabeculoplasty. A prospective study of treatment variables. Arch Ophthalmol 1984; 102: 517-519
  • 29 Heijl A. One- and two-session laser trabeculoplasty. A randomized, prospective study. Acta Ophthalmol 1984; 62: 715-724
  • 30 Weinreb RN, Ruderman J, Juster R. et al. Immediate intraocular pressure response to argon laser trabeculoplasty. Am J Ophthalmol 1983; 95: 279-286
  • 31 Elsås T, Johnsen H, Brevik TA. The immediate pressure response to primary laser trabeculoplasty – a comparison of one- and two-stage treatment. Acta Ophthalmol 1989; 67: 664-668
  • 32 Goyal S, Beltran-Agullo L, Rashid S. et al. Effect of primary selective laser trabeculoplasty on tonographic outflow facility: a randomised clinical trial. Br J Ophthalmol 2010; 94: 1443-1447
  • 33 Nagar M, Ogunyomade A, OʼBrart DPS. et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 2005; 89: 1413-1417
  • 34 Prasad N, Murthy S, Dagianis JJ. et al. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. J Glaucoma 2009; 18: 157-160
  • 35 Tojo N, Oka M, Miyakoshi A. et al. Comparison of fluctuations of intraocular pressure before and after selective laser trabeculoplasty in normal-tension glaucoma patients. J Glaucoma 2014; 23: e138
  • 36 Robin AL. Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty. Ophthalmic Surg 1991; 22: 31-37
  • 37 Birt CM, Shin DH, Reed SY. et al. One vs. two doses of 1.0 % apraclonidine for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. Can J Ophthalmol 1995; 30: 266-269
  • 38 David R, Spaeth GL, Clevenger CE. et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993; 111: 1387-1390
  • 39 Barnebey HS, Robin AL, Zimmerman TJ. et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993; 100: 1083-1088
  • 40 Barnes SD, Campagna JA, Dirks MS. et al. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2 % to apraclonidine 1.0 %. Ophthalmology 1999; 106: 2033-2037
  • 41 Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev 2017; (02) CD010746
  • 42 [Anonymous] Effect of brimonidine 0.5 % on intraocular pressure spikes following 360 % argon laser trabeculoplasty. The Brimonidine-ALT Study Group. Ophthalmic Surg Lasers 1995; 26: 404-409
  • 43 Juzych MS, Chopra V, Banitt MR. et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology 2004; 111: 1853-1859
  • 44 Baez KA, Spaeth GL. Argon laser trabeculoplasty controls one third of patients with progressive, uncontrolled open-angle glaucoma for five years. Trans Am Ophthalmol Soc 1991; 89: 47-56
  • 45 Moulin F, Haut J. Argon laser trabeculoplasty: a 10-year follow-up. Ophthalmologica 1993; 207: 196-201
  • 46 Bovell AM, Damji KF, Hodge WG. et al. Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?. Can J Ophthalmol 2011; 46: 408-413
  • 47 Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 2008; 115: 1123-1129.e3
  • 48 Asrani S, Zeimer R, Wilensky J. et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142
  • 49 Liu JHK, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004; 138: 389-395
  • 50 Tung JD, Tafreshi A, Weinreb RN. et al. Twenty-four-hour effects of bimatoprost 0.01 % monotherapy on intraocular pressure and ocular perfusion pressure. BMJ Open 2012; 2: e001106
  • 51 Liu JHK, Medeiros FA, Slight JR. et al. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009; 116: 449-454
  • 52 Liu JHK, Medeiros FA, Slight JR. et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010; 117: 2075-2079
  • 53 Orzalesi N, Rossetti L, Invernizzi T. et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566-2573
  • 54 Lee AC, Mosaed S, Weinreb RN. et al. Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients. Ophthalmology 2007; 114: 666-670
  • 55 Nagar M, Luhishi E, Shah N. Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. Br J Ophthalmol 2009; 93: 497-501
  • 56 Richter CU, Shingleton BJ, Bellows AR. et al. Retreatment with argon laser trabeculoplasty. Ophthalmology 1987; 94: 1085-1089
  • 57 Messner D, Siegel LI, Kass MA. et al. Repeat argon laser trabeculoplasty. Am J Ophthalmol 1987; 103: 113-115
  • 58 Grayson DK, Camras CB, Podos SM. et al. Long-term reduction of intraocular pressure after repeat argon laser trabeculoplasty. Am J Ophthalmol 1988; 106: 312-321
  • 59 Feldman RM, Katz LJ, Spaeth GL. et al. Long-term efficacy of repeat argon laser trabeculoplasty. Ophthalmology 1991; 98: 1061-1065
  • 60 Hong BK, Winer JC, Martone JF. et al. Repeat selective laser trabeculoplasty. J Glaucoma 2009; 18: 180-183
  • 61 Avery N, Ang GS, Nicholas S. et al. Repeatability of primary selective laser trabeculoplasty in patients with primary open-angle glaucoma. Int Ophthalmol 2013; 33: 501-506
  • 62 Damji KF, Shah KC, Rock WJ. et al. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol 1999; 83: 718-722
  • 63 Brooks AM, Gillies WE. Do any factors predict a favourable response to laser trabeculoplasty?. Aust J Ophthalmol 1984; 12: 149-153
  • 64 Tuulonen A, Airaksinen PJ, Kuulasmaa K. Factors influencing the outcome of laser trabeculoplasty. Am J Ophthalmol 1985; 99: 388-391
  • 65 AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol 2002; 134: 481-498
  • 66 Robin AL, Pollack IP. Argon laser trabeculoplasty in secondary forms of open-angle glaucoma. Arch Ophthalmol 1983; 101: 382-384
  • 67 Lieberman MF, Hoskins HD, Hetherington J. Laser trabeculoplasty and the glaucomas. Ophthalmology 1983; 90: 790-795
  • 68 Ritch R, Liebmann J, Robin A. et al. Argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmology 1993; 100: 909-913
  • 69 Harasymowycz PJ, Papamatheakis DG, Latina M. et al. Selective laser trabeculoplasty (SLT) complicated by intraocular pressure elevation in eyes with heavily pigmented trabecular meshworks. Am J Ophthalmol 2005; 139: 1110-1113
  • 70 Alvarado JA, Iguchi R, Juster R. et al. From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy. Trans Am Ophthalmol Soc 2009; 107: 167-181
  • 71 Scherer WJ. Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty. J Ocul Pharmacol Ther 2007; 23: 503-512
  • 72 Singh D, Coote MA, OʼHare F. et al. Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes. Eye (Lond) 2009; 23: 2194-2199
  • 73 Hirn C, Zehnder S, Bauer G. et al. Long-term efficacy of selective laser trabeculoplasty in patients on prostaglandin therapy. Klin Monatsbl Augenheilkd 2014; 231: 351-356
  • 74 Blyth CP, Moriarty AP, McHugh JD. Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers Med Sci 1999; 14: 105-108
  • 75 Bergeå B, Svedbergh B. Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmol 1992; 70: 454-460
  • 76 Wechsler DZ, Wechsler IB. Cystoid macular oedema after selective laser trabeculoplasty. Eye (Lond) 2010; 24: 1113
  • 77 Rhee DJ, Krad O, Pasquale LR. Hyphema following selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging 2009; 40: 493-494
  • 78 Moubayed SP, Hamid M, Choremis J. et al. An unusual finding of corneal edema complicating selective laser trabeculoplasty. Can J Ophthalmol 2009; 44: 337-338
  • 79 Knickelbein JE, Singh A, Flowers BE. et al. Acute corneal edema with subsequent thinning and hyperopic shift following selective laser trabeculoplasty. J Cataract Refract Surg 2014; 40: 1731-1735
  • 80 Lee JWY, Chan JCH, Chang RT. et al. Corneal changes after a single session of selective laser trabeculoplasty for open-angle glaucoma. Eye (Lond) 2014; 28: 47-52
  • 81 Migdal C, Hitchings R. Primary therapy for chronic simple glaucoma the role of argon laser trabeculoplasty. Trans Ophthalmol Soc U K 1985; 104: 62-66
  • 82 Elsås T, Johnsen H. Long-term efficacy of primary laser trabeculoplasty. Br J Ophthalmol 1991; 75: 34-37
  • 83 Tuulonen A, Koponen J, Alanko HI. et al. Laser trabeculoplasty versus medication treatment as primary therapy for glaucoma. Acta Ophthalmol 1989; 67: 275-280
  • 84 Rolim de Moura C, Paranhos jr. A, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007; (04) CD003919
  • 85 Ramulu PY, Parrish RK. Asking the right question in laser trabeculoplasty: “which patient”, not “which laser”?. Surv Ophthalmol 2008; 53: 652-654
  • 86 Song J, Lee PP, Epstein DL. et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma 2005; 14: 400-408